Perhydro-benzimidazol | 4089-17-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Perhydro-benzimidazol
• 英文别名: octahydro-benzoimidazole；Perhydrobenzimidazole；2,3,3a,4,5,6,7,7a-octahydro-1H-benzimidazole
• CAS: 4089-17-2
• 化学式: C₇H₁₄N₂
• 分子量: 126.202
• InChiKey: MDNGXAFGRWQHNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• TROPAN COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1785421A1

  公开（公告）日：2007-05-16

  The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X- is an anion;the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

  传统的抗胆碱药物通过吸入给药被认为可能加重与前列腺增生相关的排尿困难，并要求传统的抗胆碱药物通过吸入给药必须显示减少副作用或不良反应。 本发明涉及一种由通式（I）表示的化合物： （其中A代表; 和R1、R2、R3和R1分别是氢原子或取代基; R5是取代基; X-是阴离子;符号: 表示外向型或内向型，或它们的混合物），其盐或溶剂化产物。它们可用作通过胆碱受体介导的疾病的预防和/或治疗剂，具有减少副作用或不良反应。
• [EN] C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS<br/>[FR] COMPOSÉS DE TÉTRACYCLINE C7-FLUOROSUBSTITUÉE
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2010017470A1

  公开（公告）日：2010-02-11

  The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

  本发明涉及一种由结构式（A）表示的化合物，或其药学上可接受的盐。结构式（A）的变量在此处定义。还描述了包括结构式（A）化合物的药物组合物及其治疗用途。
• HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME
  申请人：EA PHARMA CO., LTD.

  公开号：US20160332999A1

  公开（公告）日：2016-11-17

  The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

  本发明提供了一种由公式(I)表示的化合物： 其中，每个符号如说明书中所定义，或者其药用可接受的盐。该化合物具有优越的TRPA1拮抗剂活性，并且可以提供一种用于预防或治疗涉及TRPA1拮抗剂和TRPA1的疾病的药物。
• [EN] PREPARATION OF MIXED AMIDOMAGNESIUM HALIDES<br/>[FR] PRÉPARATION D'HALOGÉNURES MIXTES D'AMIDOMAGNÉSIUM
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2017117189A1

  公开（公告）日：2017-07-06

  A composition, comprising an amidomagnesium chloride represented by the following structural formula R1R2NMgCl, and an amidomagnesium bromide represented by the following structural formula R3R4NMgBr is disclosed. Values and example values of variables R1, R2, R3, and R4 are described herein. The disclosed mixed amidomagnesium halides show an increased solubility, high reactivity and regioselectivity in facilitating the reaction of directed metalation and subsequent functionalization of aryls and heteroaryls.

  披露了一种组合物，包括由以下结构公式表示的酰胺镁氯化物R1R2NMgCl，以及由以下结构公式表示的酰胺镁溴化物R3R4NMgBr。变量R1、R2、R3和R4的值和示例值在本文中进行了描述。所披露的混合酰胺镁卤化物在促进定向金属化反应以及随后芳基和杂芳基的功能化方面显示出增加的溶解度、高反应性和区域选择性。
• [EN] TETRACYCLINE ANALOGS<br/>[FR] ANALOGUES DE TÉTRACYCLINE
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2012021712A1

  公开（公告）日：2012-02-16

  The present invention is directed to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

  本发明涉及一种由结构式(I)表示的化合物，或其药用可接受的盐。结构式(I)的变量在此定义。还描述了一种包括结构式(I)化合物及其治疗用途的药物组合物。